{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:03:17Z","timestamp":1792184597135,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,10]]},"DOI":"10.7759\/cureus.24019","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T06:44:16Z","timestamp":1649659456000},"source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of Drug-Related Problems in Chronic Kidney Disease Patients"],"prefix":"10.7759","author":[{"given":"Tasneem M","family":"Shouqair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Arman","family":"Rabbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathvik B","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin  T","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","unstructured":"Global, regional, and national burden of chronic kidney disease, 1990-2017. a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020, 395:709-33. 10.1016\/S0140-6736(20)30045-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp20X714125","article-title":"Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care","volume":"71","author":"MacRae C","year":"2021","unstructured":"MacRae C, Mercer SW, Guthrie B, Henderson D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br J Gen Pract. 2021, 71:e243-9. 10.3399\/bjgp20X714125","journal-title":"Br J Gen Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz046","article-title":"Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study","volume":"12","author":"Schmidt IM","year":"2019","unstructured":"Schmidt IM, H\u00fcbner S, Nadal J, et al.. Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. Clin Kidney J. 2019, 12:663-72. 10.1093\/ckj\/sfz046","journal-title":"Clin Kidney J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00054-4","article-title":"Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens","volume":"2","author":"Rochon PA","year":"2021","unstructured":"Rochon PA, Petrovic M, Cherubini A, et al.. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. Lancet Health Longev. 2021, 2:290-300. 10.1016\/S2666-7568(21)00054-4","journal-title":"Lancet Health Longev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.05.025","article-title":"Deprescribing in CKD: the proof is in the process","volume":"70","author":"Whittaker CF","year":"2017","unstructured":"Whittaker CF, Fink JC. Deprescribing in CKD: the proof is in the process. Am J Kidney Dis. 2017, 70:596-8. 10.1053\/j.ajkd.2017.05.025","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5414\/CP203951","article-title":"Patterns of drug use and polypharmacy burden in chronic kidney disease patients: an\u00a0experience from a secondary care hospital in United Arab Emirates","volume":"59","author":"Shouqair TM","year":"2021","unstructured":"Shouqair TM, Rabbani SA, Kurian MT. Patterns of drug use and polypharmacy burden in chronic kidney disease patients: an\u00a0experience from a secondary care hospital in United Arab Emirates. Int J Clin Pharmacol Ther. 2021, 59:519-29. 10.5414\/CP203951","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2011.10.004","article-title":"Potentially harmful drug-drug interactions in the elderly: a review","volume":"9","author":"Hines LE","year":"2011","unstructured":"Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011, 9:364-77. 10.1016\/j.amjopharm.2011.10.004","journal-title":"Am J Geriatr Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100020","article-title":"Drug-drug interactions in polypharmacy patients: the impact of renal impairment","volume":"2","author":"Papotti B","year":"2021","unstructured":"Papotti B, Marchi C, Adorni MP, Pot\u00ec F. Drug-drug interactions in polypharmacy patients: the impact of renal impairment. Curr Res Pharmacol Drug Discov. 2021, 2:100020. 10.1016\/j.crphar.2021.100020","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01030120","article-title":"Adverse drug reactions in patients with CKD","volume":"15","author":"Laville SM","year":"2020","unstructured":"Laville SM, Gras-Champel V, Moragny J, et al.. Adverse drug reactions in patients with CKD. Clin J Am Soc Nephrol. 2020, 15:1090-102. 10.2215\/CJN.01030120","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17239101","article-title":"Impact of adverse drug reactions in patients with end stage renal disease in Greece","volume":"17","author":"Spanakis M","year":"2020","unstructured":"Spanakis M, Roubedaki M, Tzanakis I, Zografakis-Sfakianakis M, Patelarou E, Patelarou A. Impact of adverse drug reactions in patients with end stage renal disease in Greece. Int J Environ Res Public Health. 2020, 17:9101. 10.3390\/ijerph17239101","journal-title":"Int J Environ Res Public Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1504371","article-title":"Drug-related problems and associated factors among patients admitted with chronic kidney disease at Jimma University Medical Center, Jimma Zone, Jimma, Southwest Ethiopia: a hospital-based prospective observational study","volume":"2019","author":"Garedow AW","year":"2019","unstructured":"Garedow AW, Mulisa Bobasa E, Desalegn Wolide A, et al.. Drug-related problems and associated factors among patients admitted with chronic kidney disease at Jimma University Medical Center, Jimma Zone, Jimma, Southwest Ethiopia: a hospital-based prospective observational study. Int J Nephrol. 2019, 2019:1504371. 10.1155\/2019\/1504371","journal-title":"Int J Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ijpp\/riab033","article-title":"Medicines optimization for patients with chronic kidney disease in the outpatient setting: the role of the clinical pharmacist","volume":"29","author":"Sch\u00fctze A","year":"2021","unstructured":"Sch\u00fctze A, Hohmann C, Haubitz M, Radziwill R, Ben\u00f6hr P. Medicines optimization for patients with chronic kidney disease in the outpatient setting: the role of the clinical pharmacist. Int J Pharm Pract. 2021, 29:587-97. 10.1093\/ijpp\/riab033","journal-title":"Int J Pharm Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.164600","article-title":"Epidemiology and referral patterns of patients with chronic kidney disease in the Emirate of Abu Dhabi","volume":"26","author":"Richards N","year":"2015","unstructured":"Richards N, Hassan M, Saleh AK, et al.. Epidemiology and referral patterns of patients with chronic kidney disease in the Emirate of Abu Dhabi. Saudi J Kidney Dis Transpl. 2015, 26:1028-34. 10.4103\/1319-2442.164600","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199920","article-title":"Chronic kidney disease in patients at high risk of cardiovascular disease in the United Arab Emirates: a population-based study","volume":"13","author":"Al-Shamsi S","year":"2018","unstructured":"Al-Shamsi S, Regmi D, Govender RD. Chronic kidney disease in patients at high risk of cardiovascular disease in the United Arab Emirates: a population-based study. PLoS One. 2018, 13:e0199920. 10.1371\/journal.pone.0199920","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.64","article-title":"Chapter 1: definition and classification of CKD","volume":"3","year":"2013","unstructured":"Chapter 1. definition and classification of CKD. Kidney Int Suppl (2011). 2013, 3:19-62. 10.1038\/kisup.2012.64","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref16","unstructured":"Portable Emergency and Primary Care Information Database (PEPID). drug interaction checker for medications, herbals, OTCs & foods. (2022). Accessed: January 30, 2022: https:\/\/www.pepid.com\/integration\/drug-interactions.asp."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref18","unstructured":"World Health Organization. The use of the WHO-UMC system for standardised case causality assessment. (2022). Accessed: January 30, 2022: https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/49.9.2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig SC","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992, 49:2229-32. 10.1093\/ajhp\/49.9.2229","journal-title":"Am J Hosp Pharm"},{"key":"ref20","article-title":"Focusing on the preventability of adverse drug reactions","volume":"27","author":"Schumock GT","year":"1992","unstructured":"Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992, 27:538.","journal-title":"Hosp Pharm"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0317-4","article-title":"Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients","volume":"17","author":"Al-Ramahi R","year":"2016","unstructured":"Al-Ramahi R, Raddad AR, Rashed AO, Bsharat A, Abu-Ghazaleh D, Yasin E, Shehab O. Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. BMC Nephrol. 2016, 17:96. 10.1186\/s12882-016-0317-4","journal-title":"BMC Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3126\/jmcjms.v9i1.38047","article-title":"Polypharmacy and potential drug-drug interactions among medications prescribed to chronic kidney disease patients","volume":"9","author":"Chaudhary SK","year":"2021","unstructured":"Chaudhary SK, Manadhar N, Adhikari L. Polypharmacy and potential drug-drug interactions among medications prescribed to chronic kidney disease patients. Janaki Med Coll J Med Sci. 2021, 9:25-32. 10.3126\/jmcjms.v9i1.38047","journal-title":"Janaki Med Coll J Med Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12080713","article-title":"Prevalence of potential drug-drug interaction risk among chronic kidney disease patients in a Spanish hospital","volume":"12","author":"Santos-D\u00edaz G","year":"2020","unstructured":"Santos-D\u00edaz G, P\u00e9rez-Pico AM, Su\u00e1rez-Santisteban M\u00c1, Garc\u00eda-Bernalt V, Mayordomo R, Dorado P. Prevalence of potential drug-drug interaction risk among chronic kidney disease patients in a Spanish hospital. Pharmaceutics. 2020, 12:10.3390\/pharmaceutics12080713","journal-title":"Pharmaceutics"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/2397847318794861","article-title":"How do we prevent the burden of extremely harmful and clinically nonbeneficial drug-drug interactions among chronic kidney disease patients?","volume":"2","author":"Fasipe OJ","year":"2018","unstructured":"Fasipe OJ, Olayemi SO, Akinyede AA, Osho PO, Ibiyemi-Fasipe OB, Osho ES. How do we prevent the burden of extremely harmful and clinically nonbeneficial drug-drug interactions among chronic kidney disease patients?. Toxicol Res Appl. 2018, 2:239784731879486. 10.1177\/2397847318794861","journal-title":"Toxicol Res Appl"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80560-2","article-title":"Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions","volume":"11","author":"Garin N","year":"2021","unstructured":"Garin N, Sole N, Lucas B, et al.. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021, 11:883. 10.1038\/s41598-020-80560-2","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00747-0","article-title":"Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy","volume":"37","author":"Sommer J","year":"2020","unstructured":"Sommer J, Seeling A, Rupprecht H. Adverse drug events in patients with chronic kidney disease associated with multiple drug interactions and polypharmacy. Drugs Aging. 2020, 37:359-72. 10.1007\/s40266-020-00747-0","journal-title":"Drugs Aging"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.270263","article-title":"Intensive monitoring of adverse drug reactions in nephrology unit of tertiary care teaching hospital","volume":"30","author":"Kareem SA","year":"2019","unstructured":"Kareem SA, Sridhar SB, Shetty MS. Intensive monitoring of adverse drug reactions in nephrology unit of tertiary care teaching hospital. Saudi J Kidney Dis Transpl. 2019, 30:1075-83. 10.4103\/1319-2442.270263","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095991","article-title":"Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease","volume":"9","author":"Sharif-Askari FS","year":"2014","unstructured":"Sharif-Askari FS, Syed Sulaiman SA, Saheb Sharif-Askari N, Al Sayed Hussain A. Development of an adverse drug reaction risk assessment score among hospitalized patients with chronic kidney disease. PLoS One. 2014, 9:e95991. 10.1371\/journal.pone.0095991","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0243-0","article-title":"Survivability of hospitalized chronic kidney disease (CKD) patients with moderate to severe estimated glomerular filtration rate (eGFR) after experiencing adverse drug reactions (ADRs) in a public healthcare center: a retrospective 3 year study","volume":"19","author":"Danial M","year":"2018","unstructured":"Danial M, Hassali MA, Ong LM, Khan AH. Survivability of hospitalized chronic kidney disease (CKD) patients with moderate to severe estimated glomerular filtration rate (eGFR) after experiencing adverse drug reactions (ADRs) in a public healthcare center: a retrospective 3 year study. BMC Pharmacol Toxicol. 2018, 19:52. 10.1186\/s40360-018-0243-0","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/90493-evaluation-of-drug-related-problems-in-chronic-kidney-disease-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:46Z","timestamp":1707507946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/90493-evaluation-of-drug-related-problems-in-chronic-kidney-disease-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,10]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.24019","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,10]]}}}